|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver stiffness in the hepatitis B virus carrier:A non-invasive marker of liver disease influenced by the pattern of transaminases显示文摘AIM: To investigate the usefulness of transient elastography by Fibroscan (FS),a rapid non-invasive technique to evaluate liver fibrosis,in the management of chronic hepatitis B virus (HBV) carriers.METHODS: In 297 consecutive HBV carriers,we studied the correlation between liver stiffness (LS),stage of liver disease and other factors potentially influencing FS measurements.In 87 chronic hepatitis B (CHB) patients,we monitored the FS variations according to the spontaneous or treatment-induced variations of biochemical activity during follow-up.RESULTS: FS values were 12.3 ± 3.3 kPa in acute hepatitis,10.3 ± 8.8 kPa in chronic hepatitis,4.3 ± 1.0 kPa in inactive carriers and 4.6 ± 1.2 kPa in blood donors.We identified the cut-offs of 7.5 and 11.8 kPa for the diagnosis of fibrosis ≥ S3 and cirrhosis respectively,showing 93.9% and 86.5% sensitivity,88.5% and 96.3% specificity,76.7% and 86.7% positive predictive value (PPV),97.3% and 96.3% negative predictive value (NPV) and 90.1% and 94.2% diagnostic accuracy.At multivariate analysis in 171 untreated carriers,fibrosis stage (t = 13.187,P < 0.001),active vs inactive HBV infection (t = 6.437,P < 0.001),alanine aminotransferase (ALT) (t = 4.740,P < 0.001) and HBV-DNA levels (t = -2.046,P = 0.042) were independently associated with FS.Necroinflammation score (t = 2.158,> 10/18 vs ≤ 10/18,P = 0.035) and ALT levels (t = 3.566,P = 0.001) were independently associated with LS in 83 untreated patients without cirrhosis and long-term biochemical remission (t = 4.662,P < 0.001) in 80 treated patients.During FS monitoring (mean follow-up 19.9 ± 7.1 mo) FS values paralleled those of ALT in patients with hepatitis exacerbation (with 1.2 to 4.4-fold increases in CHB patients) and showed a progressive decrease during antiviral therapy.CONCLUSION: FS is a non-invasive tool to monitor liver disease in chronic HBV carriers,provided that the pattern of biochemical activity is taken into account.In the inactive carrier,it identifies non-HBV-related causes of liver damage and transient reactivations.In CHB patients,it may warrant a more appropriate timing of control liver biopsies. | Filippo Oliveri Barbara Coco Pietro Ciccorossi Piero Colombatto Veronica Romagnoli Beatrice Cherubini Ferruccio Bonino Maurizia Rossana Brunetto | 2008 | World Journal of Gastroenterology2008，14，40： | 43 |
| 2 | Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report显示文摘 | Henry Lik-Yuen Chan Alex Thompson Michelle Martinot-Peignoux Teerha Piratvisuth Markus Cornberg Maurizia Rossana Brunetto Hans L. Tillmann Jia-Horng Kao Ji-Dong Jia Heiner Wedemeyer Stephen Locarnini Harry L.A. Janssen Patrick Marcellin | 2011 | Journal of Hepatology2011，，5： | 5 |
| 3 | Statements from the Taormina expert meeting on occult hepatitis B virus infection显示文摘 | Giovanni Raimondo Jean-Pierre Allain Maurizia R. Brunetto Marie-Annick Buendia Ding-Shinn Chen Massimo Colombo Antonio Craxì Francesco Donato Carlo Ferrari Giovanni B. Gaeta Wolfram H. Gerlich Massimo Levrero Stephen Locarnini Thomas Michalak Mario U. Mon | 2008 | Journal of Hepatology2008，，4： | 5 |
| 4 | Clinical epidemiology of chronic viral hepatitis B:A Tuscany real-world large-scale cohort study显示文摘AIM To build a regional database of chronic patients to define the clinical epidemiology of hepatitis B virus(HBV)-infected patients in the Tuscan public health care system.METHODS This study used a cross-sectional cohort design. We evaluated chronic viral hepatitis patients with HBV referred to the outpatient services of 16 hospital units. Information in the case report forms included main demographic data, blood chemistry data, viral hepatitis markers, instrumental evaluations, and eligibility for treatment or ongoing therapy and liver transplantation. RESULTS Of 4015 chronic viral hepatitis patients, 1096(27.3%) were HBV infected. The case report form was correctly completed for only 833 patients(64% males, 36% females; mean age 50.1 ± 15.4). Of these HBV-infected patients, 73% were Caucasian, 21% Asian, 4% Central African, 1% North African and 1% American. Stratifying patients by age and nationality, we found that 21.7% of HBV-infected patients were aged < 34 years(only 2.8% were Italian). The most represented routes of transmission were nosocomial/dental procedures(23%), mother-to-child(17%) and sexual transmission(12%). The most represented HBV genotypes were D(72%) and A(14%). Of the patients, 24.7% of patients were HBe Ag positive, and 75.3% were HBe Ag negative. Of the HBV patients 7% were anti-HDV positive. In the whole cohort, 26.9% were cirrhotic(35.8% aged < 45 years), and 47% were eligible for or currently undergoing treatment, of whom 41.9 % were cirrhotic. CONCLUSION Only 27.3% of chronic viral hepatitis patients were HBV infected. Our results provide evidence of HBV infection in people aged < 34 years, especially in the foreign population not protected by vaccination. In our cohort of patients, liver cirrhosis was also found in young adults. | Cristina Stasi Caterina Silvestri Roberto Berni Maurizia Rossana Brunetto Anna Linda Zignego Cristina Orsini Stefano Milani Liana Ricciardi Andrea De Luca Pierluigi Blanc Cesira Nencioni Donatella Aquilini Alessandro Bartoloni Giampaolo Bresci Santino Marchi Franco Filipponi Piero Colombatto Paolo Forte Andrea Galli Sauro Luchi Silvia Chigiotti Alessandro Nerli Giampaolo Corti Rodolfo Sacco Paola Carrai Angelo Ricchiuti Massimo Giusti Paolo Almi Andrea Cozzi Silvia Carloppi Giacomo Laffi Fabio Voller Francesco Cipriani | 2018 | World Journal of Hepatology2018，10，5： | 3 |
| 5 | Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease显示文摘Metabolic associated fatty liver disease(MAFLD),formerly named“nonalcoholic fatty liver disease”occurs in about one-third of the general population of developed countries worldwide and behaves as a major morbidity and mortality risk factor for major causes of death,such as cardio-vascular,digestive,metabolic,neoplastic and neuro-degenerative diseases.However,progression of MAFLD and its associated systemic complications occur almost invariably in patients who experience the additional burden of intrahepatic and/or systemic inflammation,which acts as disease accelerator.Our review is focused on the new knowledge about the brain-gut-liver axis in the context of metabolic dysregulations associated with fatty liver,where insulin resistance has been assumed to play an important role.Special emphasis has been given to digital imaging studies and in particular to positron emission tomography,as it represents a unique opportunity for the noninvasive in vivo study of tissue metabolism.An exhaustive revision of targeted animal models is also provided in order to clarify what the available preclinical evidence suggests for the causal interactions between fatty liver,dysregulated endogenous glucose production and insulin resistance. | Eleni Rebelos Patricia Iozzo Maria Angela Guzzardi Maurizia Rossana Brunetto Ferruccio Bonino | 2021 | World Journal of Gastroenterology2021，27，30： | 2 |
| 6 | 对HBV和HCV合并感染的患者通过纵向评估揭示病毒学复合谱 | Raimondo G. Brunetto M.R. Pontisso P. 陈云茹 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，0，10： | 2 |
| 7 | Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B显示文摘 | Nicola Coppola Gilda Tonziello Piero Colombatto Mariantonietta Pisaturo Vincenzo Messina Francesco Moriconi Loredana Alessio Caterina Sagnelli Daniela Cavallone Maurizia Brunetto Evangelista Sagnelli | 2013 | Journal of Infection2013，，： | 2 |
| 8 | Phase II acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecolog- ic Oncology Group Study 显示文摘 | Whitney CW Brunetto VL Zaino RJ | 2004 | Gynecol 0ncol2004，92，： | 1 |
| 9 | A phase Ⅲ trial of surgery with or without adjuvant external pelvic radiation therapy in intermediate risk endometrial adenomcarcinoma:a GOG study 显示文摘 | Keys HM Roberts JA Brunetto VL | 2004 | Gynecol Oncol2004，92，： | 1 |
| 10 | A phaseⅢtrial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma:a Gynecologic Oncology Group study显示文摘 | Keys HM Roberts JA Brunetto VL | 2004 | Gynecol Oncol2004，92，3： | 1 |
| 11 | Chronic hepatitis Be antigen (HBeAg) negative, anti- HBe positive hepatitis B: an overview 显示文摘 | Bonino F Brunetto MR | 2003 | J Hepatol2003，39，1： | 1 |
| 12 | A phase Ⅱ trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a gynecologic oncology group study显示文摘 | Brunetto V L Vanlel | 2000 | Gynecol Oncol2000，78，2： | 1 |
| 13 | Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma:a Gynecologic Oncology Group Study显示文摘 | Fleming GF Brunetto VL Cella D | 2004 | J Clin Oncol2004，22，11： | 1 |
| 14 | 'e' antigen defective hepatitis 13 virus and course of chronic infeorion显示文摘 | Brunetto MR Giarin MM Oliveri F | 1991 | Hepatol1991，13，4： | 1 |
| 15 | Phase I trial of a selective p-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies 显示文摘 | Yap T A Olmos D Brunetto AT | 2011 | J Clin Oncol2011，29，10： | 1 |
| 16 | A new role for an old marker,HBsAg显示文摘 | Brunetto MR | | 0，，4： | 1 |
| 17 | Chance and necessity of simultaneous HBsAg and anti-HBs detection in the serum of chronic HBsAg carriers显示文摘 | Brunetto MR | 2014 | J Fiepatol2014，60，3： | 1 |
| 18 | Recent progress and new trends in the treatment of hepatitis B显示文摘 | ALBERTI A BRUNETTO MR COLOMBO M | 2002 | J Med Virol2002，67，3： | 1 |
| 19 | Hepatitis B virus heterogeneity,one of many factors influencing the severity of hepatitis B显示文摘 | BONONO F BRUNETTO MR | 1993 | J Hepatol1993，18，： | 1 |
| 20 | Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers 显示文摘 | Brunetto MR Oliveri F Colombatto P Moriconi F Ciccorossi P Coco B Romagnoli V Cherubini B Moscato G Maina AM Cavallone D Bonino F | 2010 | Gastroenterology2010，139，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员